There is currently a large RCT underway, the DELIVER trial (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure; NCT03619213), which may provide further evidence of the efficacy of SGLT2 inhibitors in the treatment of HFpEF. The gene discussed is SLC5A2; the disease is heart failure.